-
November 20, 2012
Regulators in Europe have given the green light to Bayer's anticoagulant Xarelto for the treatment of pulmonary embolism and the prevention of recurrent deep vein thrombosis
Full story
-
November 05, 2012
Bayer and partner Johnson & Johnson have been given another thumbs-up for their bloodthinner Xarelto by regulators in the USA
Full story
-
July 10, 2012
Bayer and Johnson & Johnson have received good news from regulators in the USA who have agreed to speed up reviews of their oral anticoagulant Xarelto for the treatment of deep vein thrombosis and pulmonary embolism
Full story
-
April 16, 2012
Bayer’s oral anticoagulant Xarelto has been submitted for EU marketing authorisation for the treatment of pulmonary embolism and the prevention of recurrent deep vein thrombosis.
Full story
-
April 03, 2012
Following the receipt of further evidence from Bayer HealthCare of Xarelto's clinical and cost-effectiveness, NICE has issued final draft guidance recommending it an option for the prevention of stroke and systemic embolism in people with atrial fibrillation.
Full story
-
March 27, 2012
Bayer and Johnson & Johnson have presented impressive late-stage data on their blood thinner Xarelto as a treatment of pulmonary embolism and in preventing recurrent venous blood clots
Full story
-
March 13, 2012
NICE has asked Bayer for more evidence concerning the clinical and cost effectiveness of Xarelto (rivaroxaban) in the treatment of deep vein thrombosis (DVT).
Full story
-
December 20, 2011
Following new European Commission approvals, Bayer's Xarelto is now available for use in the UK for two new indications.
Full story
-
September 23, 2010
The safety of antipsychotics is in the spotlight again after research published in the British Medical Journal showed a link between their use and a risk of venous thromboembolism (VTE).
Full story